Real-world regorafenib use among patients with advanced gastrointestinal stromal tumor in the United States
PLOS One · 2026
DOI: 10.1371/journal.pone.0353357 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Ryan A Denu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. Hauptthemen laut MEDLINE: Phenylurea Compounds, Gastrointestinal Stromal Tumors, Pyridines, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer in The US.
Abstract (Originalsprache)
Background
Gastrointestinal stromal tumors (GIST) are the most common gastrointestinal soft tissue sarcoma. Tyrosine kinase inhibitors are guideline-recommended therapy; however, resistance often occurs, requiring subsequent therapy. Regorafenib is a multikinase inhibitor approved for third-line therapy. Real-world data surrounding regorafenib’s use and place in therapy are limited.
Objective
To understand real-world regorafenib utilization and patient characteristics among US patients with advanced GIST.
Methods
This retrospective cohort claims analysis used data from Merative™ MarketScan ® research databases and included patients with ≥1 pharmacy claim for regorafenib during the identification period (10/2015–5/2023) and ≥1 GIST diagnoses any time prior to/on index date (first regorafenib prescription claim). Primary outcomes included duration of therapy (DOT) and time to next therapy (TTNT). Outcomes were stratified based on prior GIST treatment during the baseline period (BL) and initial regorafenib dose (i.e., low dose [LD] or regorafenib standard dose [RSD]) as of the index date.
Results
Nearly half (45.2%) of patients received imatinib and sunitinib prior to regorafenib initiation, and 73.5% received RSD. Patients who received prior imatinib or sunitinib alone before regorafenib had a numerically longer median DOT with regorafenib than those who received both in the BL before regorafenib (142.5 days [IQR: 87–257.5] vs 95 days [IQR: 53–192]). Patients receiving LD and RSD demonstrated similar median DOT (103.0 days [IQR: 41.5, 210.5] vs 94.5 days [IQR: (35.0, 171.0]) and TTNT (143 days [IQR: 70–293] vs 141 days [IQR: 77–191]).
Conclusions
Patients on LD and RSD had similar DOT and TTNT. Acknowledging the limitations from this real-world data, patients with prior imatinib or sunitinib alone appeared to have longer DOT on regorafenib than those who received both. Further research is warranted to explore the clinical benefits of these differences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
- Bayer HealthCare Pharmaceuticals Inc, Whippany, New Jersey, United States of America.
- Cencora, Conshohocken, Pennsylvania, United States of America.
ORCID-Profile: Ryan A Denu
Förderung
- Bayer in The US
Zitieren
APA
Denu, R. A., Appukkuttan, S., Hocum, B., Liao, N., Katta, A., Heo, J., Schroader, B., Singh, R., Babajanyan, S., & Somaiah, N. (2026). Real-world regorafenib use among patients with advanced gastrointestinal stromal tumor in the United States. PLOS One. https://doi.org/10.1371/journal.pone.0353357
Vancouver
Denu RA, Appukkuttan S, Hocum B, Liao N, Katta A, Heo J, et al. Real-world regorafenib use among patients with advanced gastrointestinal stromal tumor in the United States. PLOS One. 2026. doi:10.1371/journal.pone.0353357
BibTeX
@article{Denu2026,
author = {Denu, Ryan A and Appukkuttan, Sreevalsa and Hocum, Brian and Liao, Nick and Katta, Arvind and Heo, Jihaeng and Schroader, Bridgette and Singh, Risho and Babajanyan, Svetlana and Somaiah, Neeta},
title = {Real-world regorafenib use among patients with advanced gastrointestinal stromal tumor in the United States},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0353357}
}
EUVIMED